Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Steglatro for Adults with T2D

Pfizer news release; 2017 Dec 22

FDA has approved Steglatro (ertugliflozin) oral tablets for the treatment of adults with type 2 diabetes. The approval was granted to Merck and Pfizer Inc.

Indications: Steglatro is a sodium glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Dosage and administration: Recommended starting dose is 5 mg once daily, taken in the morning, with or without food. Increase dose to 15 mg once daily in those tolerating Steglatro and needing additional glycemic control. Assess renal function before initiating Steglatro and periodically thereafter.

Adverse reactions: The most common adverse reactions associated with Steglatro (incidence ≤5%) were female genital mycotic infections.

Citation:

FDA approves SGLT2 inhibitor Steglatro (ertugliflozin) for adults with type 2 diabetes. [news release]. Merck, Pfizer: December 22, 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209803s000lbl.pdf. Accessed December 24, 2017.

This Week's Must Reads

Androgen Deprivation Therapy & Risk of Depression, Cancer; ePub 2019 Feb 12; Deka, Rose, et al

QOL in Patients with Low-Risk PC Treated with HRT, JAMA Oncol; ePub 2019 Feb 14; Bruner, et al

Hospital Competition & Prostate Cancer Outcomes, Cancer; ePub 2019 Feb 1; Aggarwal, et al

Insurance Status & Stage of Prostate Ca Diagnosis, Cancer Epidemiol; 2019 Apr; Ramirez, Morano, et al

Agent Orange Exposure & Prostate Ca Outcomes, J Urol; ePub 2019 Jan 8; Etheridge, et al

Must Reads in Diabetes

Insulin Management in Patients with T2D, Lancet; ePub 2019 Feb 22; Bergenstal, et al

Hospitalization Rates in Young-Onset Diabetes, Ann Intern Med; ePub 2019 Jan 15; Ke, Lau, et al

Long-Term Absolute Risk for CVD by FG Level, Diabetes Care; ePub 2019 Jan 7; Bancks, et al

Prediabetes Status & Lifestyle Modification , J Am Board Fam Med; 2019 Jan 4; Owei, et al

Second-Line ADMs & CV Events in T2D, JAMA Netw Open; ePub 2018 Dec 21; O’Brien, et al